AR071617A1 - Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos. - Google Patents

Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos.

Info

Publication number
AR071617A1
AR071617A1 ARP090101596A ARP090101596A AR071617A1 AR 071617 A1 AR071617 A1 AR 071617A1 AR P090101596 A ARP090101596 A AR P090101596A AR P090101596 A ARP090101596 A AR P090101596A AR 071617 A1 AR071617 A1 AR 071617A1
Authority
AR
Argentina
Prior art keywords
alkyl
3alkyl
same
different
independently selected
Prior art date
Application number
ARP090101596A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41265326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR071617(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR071617A1 publication Critical patent/AR071617A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Reivindicacion 1: Un compuesto de la formula (1) en donde a es 0, 1, 2 o 3; cada R1 es el mismo o diferente y es seleccionado independientemente de halo, alquilo, haloalquilo, -OR6, -CO2R6, -NR6R7, y -CN; el anillo A es seleccionado de cicloalquilo C3-6, fenilo, heterociclo de 5 o 6 miembros y heteroarilo de 5 o 6 miembros, el heterociclo y el heteroarilo teniendo cada uno 1 o 2 heteroátomos seleccionados de N, O y S; cada uno de Q1, Q2, Q3 y Q4 es CH, C-R2 o N, en donde no más de uno de Q1, Q2, Q3,y Q4 es N; cada R2 es el mismo o diferente y es seleccionado independientemente de halo, alquilo, haloalquilo, y -OR6; W es seleccionado de -O- y -S-; R3 es seleccionado de H, alquilo, haloalquilo-, -alquilen-OH,-NR6R7, -cicloalquilo C3-6,-alquilen-C(O)-OH, -alquilen-NH2, y Het; en donde el R3 cicloalquilo C3-6 es opcionalmente substituido con 1 o 2 substituyentes los cuales son los mismos o diferentes y son seleccionados independientemente de halo, alquilo c1-3, haloC1-3alquilo, OH, O-alquilo C1-3, oxo, Salquil C1-3, SO2, NH2, N(H)alquilo C1-3 y N(alquil C1-3)2; Het es un heterociclo de 5 o 6 miembros que tienen 1 o 2 heteroátomos seleccionados de N, O y S y opcionalmente substituidos con 1 o 2 substituyentes los cuales son los mismos o diferentes y cada uno es seleccionado independientemente de halo, alquilo C1-3, haloC1-3alquilo, O-alquilo C1-3, alquilen C1-3-O-alquilo C1-3, OH, alquilen C1-3-OH, oxo, SO2-alquil C1-3, alquilen C1-3-SO2alquil C1-3, NH2, N(H)alquilo C1-3, N(alquil C1-3)2, CN, y -CH2CN; R4 es seleccionado de H, alquilo, haloalquilo, alquenilo, -OR6, -R5-OR6, -R5-CO2R6, -R5-SO2R6, -R5-Het, -R5-C(O)-Het, -N(H)R8, -N(CH3)R8, y -R5-NR6R7; cada R5 es el mismo o diferente y es independientemente alquileno C1-4; cada R6 y cada R7 es el mismo o diferente y es seleccionado independientemente de H, alquilo, haloalquilo, -C(O)-alquilo, y -C(O)cicloalquilo; R8 es seleccionado de H, alquilo (opcionalmente substituido por -OH), haloalquilo, cicloalquilo C3-6, -R5-cicloalquilo C3-6, Het2, -R5-Het2 -R5-OR6, -R5-O-R5-OR6, -R5-C(O)2R6, -R5-C(O)NR6R7, -R5-N(H)C(O)-R6, -R5-N(H)C(O)-R5-OR6, -R5-N(H)C(O)2-R6, -R5-NR6R7, -R5-S(O)2R6, -R5-CN, y -R5-N(H)S(O)2R6; en donde el R8 cicloalquilo C3-6es opcionalmente substituido con 1 o 2 substituyentes los cuales son los mismos o diferentes y son seleccionados independientemente de halo, alquilo C1-3, haloC1-3alquilo, OH, O-alquilo C1-3, oxo, S(alquil C1-3), SO2(alquil C1-3), NH2, N(H)alquilo C1-3 y N(alquil C1-3)2, y N(H)SO2alquilo C1-3; y Het2 es un heterociclo de 4 a 6 miembros que tiene 1 o 2 heteroátomos seleccionados de N, O y S y es opcionalmente substituido con 1, 2, 3, 4 o 5 alquil C1-3 o 1 o 2 substituyentes los cuales son los mismos o diferentes y cada uno son seleccionados independientemente de halo, alquilo C1-3, haloC1-3alquilo, O-alquilo C1-3, alquilen C1-3-O-alquilo C1-3, alquilen C1-3-OH, oxo, SO2(alquil C1-3), alquilen C1-3-SO2(alquil C1-3), NH2, N(H)alquilo C1-3, N(alquil C1-3)2, N(H)SO2alquil C1-3, C(O)(alquil C1-3), CO2(alquil C1-4), CN, y -CH2CN; y R9 y R10 son seleccionados independientemente de H y alquilo, y sales farmacéuticamente aceptables de los mismos.
ARP090101596A 2008-05-06 2009-05-04 Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos. AR071617A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5074408P 2008-05-06 2008-05-06

Publications (1)

Publication Number Publication Date
AR071617A1 true AR071617A1 (es) 2010-06-30

Family

ID=41265326

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101596A AR071617A1 (es) 2008-05-06 2009-05-04 Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos.

Country Status (35)

Country Link
US (6) US8415345B2 (es)
EP (2) EP2282636B1 (es)
JP (1) JP5426664B2 (es)
KR (1) KR101628746B1 (es)
CN (1) CN102083312B (es)
AR (1) AR071617A1 (es)
AU (1) AU2009244491B2 (es)
BR (1) BRPI0912541B8 (es)
CA (1) CA2723396C (es)
CL (1) CL2009001065A1 (es)
CO (1) CO6321189A2 (es)
CY (1) CY1117615T1 (es)
DK (1) DK2282636T3 (es)
DO (1) DOP2010000326A (es)
EA (1) EA019349B1 (es)
ES (1) ES2576684T3 (es)
HK (1) HK1147907A1 (es)
HR (1) HRP20160447T1 (es)
HU (1) HUE028820T2 (es)
IL (1) IL209018A (es)
JO (1) JO3408B1 (es)
MA (1) MA32369B1 (es)
MX (1) MX2010012074A (es)
MY (1) MY155317A (es)
NZ (1) NZ588970A (es)
PE (1) PE20091952A1 (es)
PL (1) PL2282636T3 (es)
RS (1) RS54725B1 (es)
SG (1) SG190624A1 (es)
SI (1) SI2282636T1 (es)
TW (1) TWI432430B (es)
UA (1) UA103319C2 (es)
UY (1) UY31806A (es)
WO (1) WO2009137391A2 (es)
ZA (1) ZA201007960B (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
BRPI0814423B1 (pt) 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
JP2011513331A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
US20110003809A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
CA2716951A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
US20110003859A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2010104899A1 (en) * 2009-03-12 2010-09-16 Glaxosmithkline Llc Thiazole sulfonamide and oxazole sulfonamide kinase inhibitors
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
WO2011044415A1 (en) * 2009-10-08 2011-04-14 Glaxosmithkline Llc Combination
CA2777085A1 (en) * 2009-10-08 2011-04-14 Glaxosmithkline Llc Combination
KR20120097496A (ko) * 2009-10-12 2012-09-04 글락소스미스클라인 엘엘씨 조합물
RS59181B1 (sr) 2009-10-16 2019-10-31 Novartis Ag Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
BR112012012156A2 (pt) 2009-11-06 2015-09-08 Plexxikon Inc compostos e métodos para modulação de cinase, e indicações para esta
EP2498608A4 (en) * 2009-11-10 2013-04-24 Glaxosmithkline Llc BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS
AU2011209234B2 (en) * 2010-01-27 2015-05-07 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
CA2803055A1 (en) * 2010-06-25 2011-12-29 Novartis Ag Heteroaryl compounds and compositions as protein kinase inhibitors
EP2601185B1 (en) * 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
US20130172378A1 (en) * 2010-09-14 2013-07-04 Glaxosmithkline Llc Combination of BRAF and VEGF Inhibitors
WO2012061683A2 (en) * 2010-11-05 2012-05-10 Glaxosmithkline Llc Methods for treating cancer
EP2640387A4 (en) * 2010-11-19 2014-08-20 Glaxosmithkline Ip No 2 Ltd METHOD OF TREATMENT USING BRAF INHIBITOR
EP3459945A1 (en) * 2011-01-25 2019-03-27 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors for use in the treatment of cancer
BR112013020041B1 (pt) 2011-02-07 2021-11-23 Plexxikon, Inc Compostos e composições para a modulação de quinases e uso dos mesmos
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
WO2012113774A1 (en) 2011-02-24 2012-08-30 Nerviano Medical Sciences S.R.L. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
WO2013019620A2 (en) * 2011-07-29 2013-02-07 Glaxosmithkline Llc Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody
US8389723B1 (en) * 2011-08-24 2013-03-05 Glaxosmithkline Llc Deuterated benzene sulfonamide thiazole compounds
JP6150813B2 (ja) 2011-11-11 2017-06-21 ノバルティス アーゲー 増殖性疾患の治療方法
WO2013078264A1 (en) 2011-11-23 2013-05-30 Novartis Ag Pharmaceutical formulations
US20130184280A1 (en) * 2011-12-21 2013-07-18 Telik, Inc. Substituted thiazoles as vegfr2 kinase inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
BR112015003418A2 (pt) 2012-08-17 2017-07-04 Hoffmann La Roche produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica.
JP2015527374A (ja) 2012-09-04 2015-09-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ アジュバント癌治療の方法
BR112015009134A2 (pt) * 2012-10-25 2017-07-04 Glaxosmithkline Llc combinação
KR102271794B1 (ko) * 2012-11-09 2021-07-01 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항암 활성을 나타내는 벤젠 설폰아미드 티아졸 화합물
CN103936728B (zh) * 2013-01-18 2016-08-10 通化济达医药有限公司 噻唑激酶抑制剂
CN103936730A (zh) * 2013-01-22 2014-07-23 通化济达医药有限公司 苯磺酰胺噻唑激酶抑制剂
CN103965170A (zh) * 2013-01-24 2014-08-06 通化济达医药有限公司 苯磺酰胺吡唑激酶抑制剂
CN103965180B (zh) * 2013-01-24 2016-09-07 通化济达医药有限公司 苯磺酰胺噁唑和噻唑激酶抑制剂
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN104109159A (zh) * 2013-04-17 2014-10-22 杭州普晒医药科技有限公司 苯磺酰胺噻唑化合物的新晶型及其制备方法
TWI634114B (zh) 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
EP3004060B1 (en) * 2013-05-30 2019-11-27 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
KR20160013049A (ko) 2013-06-03 2016-02-03 노파르티스 아게 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물
CN104540822B (zh) * 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
WO2015059677A1 (en) 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
CN103588767B (zh) * 2013-11-20 2016-01-20 苏州明锐医药科技有限公司 达拉菲尼的制备方法
CN103880831A (zh) * 2013-11-25 2014-06-25 镇江圣安医药有限公司 N-(2-氟苯基)-2,6-二氟苯磺酰胺的衍生物及其应用
MX2016007653A (es) 2013-12-12 2016-10-13 Novartis Ag Combinaciones de trametinib, panitumumab y dabrafenib para el tratamiento del cancer.
ES2822125T3 (es) 2013-12-28 2021-04-29 Guardant Health Inc Métodos y sistemas para detectar variantes genéticas
WO2015105822A1 (en) * 2014-01-07 2015-07-16 Glaxosmithkline Llc Cancer treatment method
JP6636014B2 (ja) * 2014-09-12 2020-01-29 ノバルティス アーゲー Ｒａｆキナーゼ阻害剤としての化合物および組成物
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
WO2016059548A1 (en) 2014-10-13 2016-04-21 Mylan Laboratories Ltd Processes for the preparation of dabrafenib
CN105651927B (zh) * 2014-11-14 2019-12-13 泰州复旦张江药业有限公司 一种伐地昔布/帕瑞昔布有关物质的rt-hplc检测方法
IL254697B (en) * 2015-03-31 2022-08-01 Syros Pharmaceuticals Inc Methods for stratifying patients for treatment with retinoic acid alpha receptor agonists
CN106366080A (zh) * 2015-07-21 2017-02-01 重庆大学 一种抗黑色素瘤的化合物及其应用
CN108348513A (zh) 2015-08-28 2018-07-31 诺华股份有限公司 用于治疗或预防癌症的ribociclib与达拉菲尼的组合
EP3355886A1 (en) * 2015-08-28 2018-08-08 Novartis AG Pharmaceutical combination comprising the pi3k inhibitor alpelisib and the b-raf inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
US20190263796A1 (en) 2016-09-23 2019-08-29 Cellipse Lim kinase inhibitors, pharmaceutical composition and method of use in limk-mediated diseases
US20180125812A1 (en) 2016-11-04 2018-05-10 Emory University Dehydroacetic Acid (DHAA) and Derivative for Uses in Treating Cancer
JP7341060B2 (ja) 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
EP3648744A1 (en) * 2017-07-05 2020-05-13 Novartis AG Novel pharmaceutical composition
JP7416716B2 (ja) 2017-12-28 2024-01-17 トラクト ファーマシューティカルズ インコーポレイテッド 円柱上皮幹細胞のための幹細胞培養系およびそれに関連した使用法
CN108129471A (zh) * 2018-03-20 2018-06-08 韩邦森 一种噻唑取代嘧啶类化合物的合成工艺
CN111936141A (zh) 2018-03-30 2020-11-13 诺华股份有限公司 包含达拉菲尼、曲美替尼和erk抑制剂的三重药物组合
EP3560516A1 (en) 2018-04-27 2019-10-30 Bergen Teknologioverforing AS Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
US20210196714A1 (en) * 2018-06-18 2021-07-01 Duke University Compositions and methods for treating disorders characterized with aberrant ras/mapk signaling
CN112867803A (zh) 2018-10-16 2021-05-28 诺华股份有限公司 单独的或与免疫标志物组合的肿瘤突变负荷作为生物标志物用于预测对靶向疗法的应答
WO2020124397A1 (en) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
GB201901507D0 (en) 2019-02-04 2019-03-27 St Georges Hospital Medical School New treatment
KR20220131229A (ko) * 2019-12-05 2022-09-27 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) N-(3-(5-(피리미딘-4-일)티아졸-4-일)페닐)설폰아미드 화합물 및 이의 용도
EP4110341A2 (en) 2020-02-28 2023-01-04 Novartis AG A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor
JP2023515817A (ja) 2020-02-28 2023-04-14 ノバルティス アーゲー ダブラフェニブ、ｅｒｋ阻害剤及びｓｈｐ２阻害剤を含む三重の医薬品の組合せ
IL297743B1 (en) 2020-04-30 2024-02-01 Medshine Discovery Inc Compounds containing benzosulatum
TW202231279A (zh) * 2020-12-02 2022-08-16 美商潤新生物公司 特定化學個體、組合物及方法
CN112724052B (zh) * 2021-01-21 2021-09-07 南京艾美斐生物医药科技有限公司 一种gpr101蛋白受体抑制剂及其制备和应用
CN113024384A (zh) * 2021-03-16 2021-06-25 湖南工程学院 一种2-氟-3-硝基苯甲酸中间体原料的合成方法
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
CN113717053B (zh) * 2021-09-02 2023-10-27 合肥利夫生物科技有限公司 一种酪氨酸激酶抑制剂关键中间体的合成方法
WO2023070076A1 (en) * 2021-10-22 2023-04-27 The Board Of Trustees Of The University Of Illinois Compounds for cancers driven by braf mutation
US20230303509A1 (en) * 2022-03-28 2023-09-28 Nikang Therapeutics, Inc. Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
WO2023240024A1 (en) * 2022-06-08 2023-12-14 Nikang Therapeutics, Inc. Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
CN115260179A (zh) * 2022-08-23 2022-11-01 江苏大学 一种2-氨基嘧啶衍生物及其制备方法和应用

Family Cites Families (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015764D0 (en) 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
KR970069028A (ko) 1996-04-01 1997-11-07 김은영 화학색전용 에멀젼의 제조방법
AU706497B2 (en) 1996-04-03 1999-06-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU721952B2 (en) 1996-04-03 2000-07-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2249665A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000509371A (ja) 1996-04-03 2000-07-25 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
CA2249615A1 (en) 1996-04-03 1997-10-09 Robert Gomez Inhibitors of farnesyl-protein transferase
CA2250936A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9609441D0 (en) 1996-05-04 1996-07-10 Zeneca Ltd Process
WO1998000134A1 (en) 1996-06-28 1998-01-08 Merck & Co., Inc. Fibrinogen receptor antagonists
US5755056A (en) 1996-07-15 1998-05-26 Remington Arms Company, Inc. Electronic firearm and process for controlling an electronic firearm
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
EP0977892A1 (en) 1997-04-24 2000-02-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and compositions for use in modulating expression of matrix metalloproteinase genes
CN1155600C (zh) * 1997-09-05 2004-06-30 葛兰素集团有限公司 2,3-二芳基吡唑并[1,5-b]哒嗪衍生物,其制备方法和用作环氧酶2抑制剂
BRPI9909191B8 (pt) 1998-03-27 2021-07-06 Janssen Pharmaceutica Nv derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
GB9812768D0 (en) 1998-06-13 1998-08-12 Zeneca Ltd Methods
ATE266012T1 (de) 1998-10-22 2004-05-15 Hoffmann La Roche Thiazole derivate
CA2349567A1 (en) 1998-11-03 2000-05-11 Glaxo Group Limited Pyrazolopyridine derivatives as selective cox-2 inhibitors
EP1144371B1 (en) * 1999-01-13 2005-11-09 Warner-Lambert Company Llc Benzenesulphonamide derivatives and their use as mek inhibitors
FR2788770B1 (fr) 1999-01-21 2001-02-16 Oreal Nouveaux 2-sulfonylaminophenols cationiques, leur utilisation a titre de coupleur pour la teinture d'oxydation, compositions les comprenant et procedes de teinture
WO2000052008A1 (en) 1999-02-27 2000-09-08 Glaxo Group Limited Pyrazolopyridines
GB9904930D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Thiazoloindolinone compounds
AU4556800A (en) 1999-04-27 2000-11-10 Smithkline Beecham Plc Novel treatment
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
CA2375909A1 (en) 1999-07-19 2001-01-25 Shionogi & Co., Ltd. Tricyclic compounds bearing acyloxymethoxycarbonyl pendants
PL353476A1 (en) 1999-07-23 2003-11-17 Shionogi & Co, Ltd. Th2 differentiation inhibitors
WO2001007401A1 (fr) 1999-07-23 2001-02-01 Shionogi & Co., Ltd. Composes tricycliques et compositions medicamenteuses les contenant
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
CA2385592C (en) 1999-09-17 2011-01-11 Bing-Yan Zhu Benzamides and related inhibitors of factor xa
BR0014078A (pt) 1999-09-17 2002-12-31 Millennium Pharm Inc Inibidores de fator xa
JP2003512467A (ja) 1999-10-27 2003-04-02 ノバルティス アクチエンゲゼルシャフト チアゾールおよびイミダゾ（４，５−ｂ）ピリジン化合物ならびにそれらの医薬用途
DE60037597T2 (de) * 1999-11-22 2008-12-11 Smithkline Beecham P.L.C., Brentford Imidazol- Derivate
AU2001234689A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Bivalent phenylene inhibitors of factor xa
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
NZ521068A (en) 2000-03-29 2005-04-29 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
MXPA02009763A (es) 2000-04-04 2003-03-27 Shionogi & Co Composiciones aceitosas las cuales contienen farmacos altamente solubles en grasa.
WO2001077091A2 (en) 2000-04-05 2001-10-18 Tularik Inc. Ns5b hcv polymerase inhibitors
AU2001244610A1 (en) 2000-04-05 2001-10-23 Shionogi And Co., Ltd. Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
AU2001259242A1 (en) 2000-04-28 2001-11-12 Glaxo Group Limited Process for the preparation of chemical compounds
WO2001087857A1 (en) 2000-05-16 2001-11-22 Nippon Soda Co., Ltd. Phenyloxazole compounds and fungicides for agricultural and horticultural use
DE60104697T2 (de) 2000-06-13 2005-08-04 Eli Lilly And Co., Indianapolis Sulfonamid-derivate
JP2004501913A (ja) 2000-06-23 2004-01-22 ブリストル−マイヤーズ　スクイブ　ファーマ　カンパニー ヘテロアリール−フェニル置換Ｘａ因子阻害剤
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AU2002214626A1 (en) 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Quaternary amines and related inhibitors of factor xa
WO2002048148A2 (en) 2000-12-15 2002-06-20 Glaxo Group Limited Pyrazolopyridine derivatives
ES2245380T3 (es) 2000-12-15 2006-01-01 Glaxo Group Limited Pirazolopiridinas.
EP1359911A2 (en) 2000-12-29 2003-11-12 Alteon, Inc. Method for treating fibrotic diseases or other indications ivc
EP1364949A4 (en) 2001-02-02 2005-11-23 Takeda Pharmaceutical INHIBITOR OF JNK
AU2002247208A1 (en) 2001-03-05 2002-09-19 Icos Corporation Selective pde3b inhibitors and use of the same in therapy
JP2004529119A (ja) 2001-03-08 2004-09-24 スミスクライン ビーチャム コーポレーション ピラゾロピリジン誘導体
US20050107400A1 (en) 2001-03-30 2005-05-19 Boyd Leslie F. Use of pyrazolopyridines as therapeutic compounds
JP4237497B2 (ja) 2001-03-30 2009-03-11 スミスクライン ビーチャム コーポレーション ピラゾロピリジン類、その調製方法及びその治療用化合物としての使用
JP4219171B2 (ja) 2001-04-10 2009-02-04 スミスクライン ビーチャム コーポレーション 抗ウイルス性ピラゾロピリジン化合物
NZ529043A (en) 2001-04-16 2006-11-30 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
DE60204452T2 (de) 2001-04-27 2005-12-15 Smithkline Beecham Corp. Pyrazolo[1,5a]Pyridinderivate
EP1401427A4 (en) 2001-06-06 2004-12-01 Agouron Pharma NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF, PROCESSES FOR THE PREPARATION THEREOF
US7186714B2 (en) 2001-06-21 2007-03-06 Smithkline Beecham Corporation Imidazo[1,2-α]pyridine derivatives for the prophylaxis and treatment of herpes viral infections
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
WO2003022832A1 (en) 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans and pyrroles as raf kinase inhibitors
DE60220525T2 (de) 2001-09-07 2008-02-07 Smithkline Beecham Corp. Pyrazolo-pyridine für die behandlung von herpes-ansteckungen
GB0123589D0 (en) 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
ES2262893T3 (es) 2001-10-05 2006-12-01 Smithkline Beecham Corporation Derivados de imidazo-piridina para su uso en el tratamiento de infeccion virica por herpes.
DE10154125A1 (de) 2001-10-25 2003-05-22 Zeiss Carl Semiconductor Mfg Messverfahren und Messsystem zur Vermessung der Abbildungsqualität eines optischen Abbildunsgssystems
WO2003047523A2 (en) * 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
JP2005516916A (ja) 2001-12-11 2005-06-09 スミスクライン ビーチャム コーポレーション 抗ヘルペス薬としてのピラゾロ−ピリジン誘導体
EP1509614A4 (en) 2002-02-15 2007-09-12 Gen Hospital Corp MAP KINASE INHIBITORS FOR REGULATING TUMOR ASSOCIATED ANTIGENE EXPRESSION
US7247626B2 (en) 2002-03-07 2007-07-24 Smithkline Beecham Corporation Pyrazolopyrimidine derivatives and pharmaceutical compositions containing them
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
JP2005529889A (ja) 2002-04-26 2005-10-06 ファイザー・プロダクツ・インク ピリミジン−２，４，６−トリオンメタロ−プロテイナーゼ阻害剤
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
WO2003095455A2 (en) 2002-05-10 2003-11-20 Smithkline Beecham Corporation Substituted pyrazolopyrimidines
WO2004000318A2 (en) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
JP2006505522A (ja) 2002-08-08 2006-02-16 スミスクライン ビーチャム コーポレーション チオフェン化合物
AU2003272361A1 (en) 2002-09-11 2005-04-11 Sequenom, Inc. Methods for identifying subjects at risk of melanoma and treatments thereof
US20040121375A1 (en) 2002-09-30 2004-06-24 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
AU2003295408A1 (en) 2002-11-06 2004-06-03 Smithkline Beecham Corporation Sulfonamides
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
WO2004058713A1 (en) 2002-12-20 2004-07-15 Irm Llc Differential tumor cytotoxocity compounds and compositions
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) * 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US6893159B1 (en) 2003-01-27 2005-05-17 Christopher Eugene Hosmer Lubrication free connection
AU2004218456A1 (en) 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists.
US8178570B2 (en) 2003-04-09 2012-05-15 Exelixis, Inc. Tie-2 modulators and methods of use
EA200501607A1 (ru) 2003-04-14 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи Замещённые фенилалкановые кислоты
BRPI0409409A (pt) 2003-04-14 2006-04-25 Novartis Ag métodos para tratar doenças proliferativas e para monitorar a eficácia de tratamento de doenças proliferativas
MXPA05011537A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Acidos aminocaboxilicos sustituidos.
MXPA05011539A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b.
MXPA05011524A (es) 2003-04-30 2006-03-21 Inst For Pharm Discovery Inc Acidos carboxilicos sustituidos.
KR20060006954A (ko) 2003-04-30 2006-01-20 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 단백질 티로신 포스파타제-１ｂ 억제제로서의 페닐 치환된카르복실산
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
BRPI0411275A (pt) 2003-06-10 2006-08-01 Kalypsys Inc compostos de carbonila como inibidores de histona deacetilase para tratamento de doenças; composição farmacêutica; método de modular a atividade catalìtica de hdac; método de tratar doença em um indivìduo; utilização de um composto ou composição; método de inibir hdac
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
GB0315517D0 (en) 2003-07-02 2003-08-06 Barrett Kevin J Earth clamp
WO2005007090A2 (en) 2003-07-03 2005-01-27 President And Fellows Of Harvard College Inhibitors of the map kinase pathway
WO2005012298A1 (en) * 2003-07-30 2005-02-10 Cyclacel Limited Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
AU2003286447A1 (en) 2003-10-16 2004-06-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
CA2542880A1 (en) 2003-10-21 2005-05-12 Cyclacel Limited Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005070900A1 (en) 2004-01-22 2005-08-04 Altana Pharma Ag N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
NZ548884A (en) 2004-01-30 2010-06-25 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
US20070179131A1 (en) 2004-03-11 2007-08-02 Jian Jin Novel M3 Muscarinic Acetylcholine Receptor Antagonists
JP2007528420A (ja) 2004-03-11 2007-10-11 グラクソ　グループ　リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
EP2360142A1 (en) 2004-03-11 2011-08-24 Elan Pharmaceuticals Inc. N-substituted benzene sulfonamides
EP1744788A4 (en) 2004-03-19 2010-08-18 Penn State Res Found COMBINATIVE METHODS AND COMPOSITIONS FOR TREATING MELANOMA
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
US20050267032A1 (en) 2004-05-21 2005-12-01 Icagen, Inc. Sulfone-containing prodrugs
GB0411791D0 (en) 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
PL1761528T3 (pl) 2004-06-11 2008-05-30 Japan Tobacco Inc Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka
JP2007223903A (ja) 2004-07-09 2007-09-06 Takeda Chem Ind Ltd 新規な固体分散体およびその製造方法
PE20060574A1 (es) * 2004-07-28 2006-06-24 Glaxo Group Ltd Derivados de arilpiperazina sulfonamida como agonistas de los receptores de secretagogos de la hormona del crecimiento (ghs)
SG155222A1 (en) 2004-08-13 2009-09-30 Genentech Inc Thiazole based inhibitors of atp-utilizing enzymes
WO2006026305A1 (en) 2004-08-31 2006-03-09 Biogen Idec Ma Inc Pyrimidinylpyrazoles as tgf-beta inhibitors
GB0420424D0 (en) 2004-09-14 2004-10-20 Ionix Pharmaceuticals Ltd Therapeutic compounds
JP4810814B2 (ja) 2004-09-15 2011-11-09 オムロン株式会社 光学シート及び面光源装置
EP1640018A1 (en) 2004-09-24 2006-03-29 Universität Zürich Combinational therapy for treating cancer
CN101061116A (zh) 2004-09-24 2007-10-24 詹森药业有限公司 磺酰胺化合物
JP2008516962A (ja) 2004-10-15 2008-05-22 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管傷害を治療する方法
CA2584794A1 (en) 2004-10-26 2006-05-04 Third-Order Nanotechnologies, Inc. Tricyclic spacer systems for nonlinear optical devices
EP1805136A1 (en) * 2004-10-28 2007-07-11 The Institutes for Pharmaceutical Discovery, LLC Substituted phenylalkanoic acids
JP2008518937A (ja) * 2004-10-28 2008-06-05 ジ インスティチューツ フォー ファーマシューティカル ディスカバリー、エルエルシー 置換カルボン酸
US20060134068A1 (en) * 2004-11-09 2006-06-22 Mount Sinai School Of Medicine Of New York University Treatment of cancer by simultaneous inhibiton of BRAF and restoration or mimicry of p16INK4A activity
EP1810972B1 (en) 2004-11-10 2012-01-25 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and pharmaceutical use thereof
JP2008520579A (ja) 2004-11-15 2008-06-19 グラクソ グループ リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
WO2006055503A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
AU2005307818A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocyclylbiphenyl derivates as protein Tyrosine phosphatase inhibitors
WO2006055708A2 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids for the treatment of diabetes
EP1814869A2 (en) 2004-11-18 2007-08-08 The Institutes for Pharmaceutical Discovery, LLC Substituted amino acids as protein tyrosine phosphatase inhibitors
WO2006064375A2 (en) 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
US7812022B2 (en) * 2004-12-21 2010-10-12 Glaxosmithkline Llc 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
ATE430747T1 (de) 2004-12-21 2009-05-15 Smithkline Beecham Corp 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
CA2594726C (en) 2005-01-14 2013-03-19 Chemocentryx, Inc. Heteroaryl sulfonamides and ccr2
EP2527337A1 (en) * 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
EP1904491A2 (en) 2005-05-31 2008-04-02 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
EP2395004B1 (en) 2005-06-22 2016-01-20 Plexxikon Inc. Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors
ATE556568T1 (de) 2005-06-30 2012-05-15 Led Roadway Lighting Ltd Verfahren und system zur luminanzcharakterisierung
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
US10144970B2 (en) 2005-07-13 2018-12-04 University Of Utah Research Foundation Methods and compositions related to a BRAF mutation and microsatellite stability
US7713960B2 (en) 2005-07-22 2010-05-11 University Of South Florida Inhibition of the Raf/Mek/P-Erk pathway for treating cancer
RU2405770C2 (ru) 2005-09-27 2010-12-10 Сионоги Энд Ко., Лтд. Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2
US7910742B2 (en) 2005-09-29 2011-03-22 Abbott Laboratories Survivin inhibitors
RU2008112691A (ru) 2005-10-03 2009-10-10 Оно Фармасьютикал Ко., Лтд. (Jp) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
EP1945620A2 (en) 2005-11-07 2008-07-23 Irm Llc Compounds and compositions as ppar modulators
JP2009514973A (ja) 2005-11-07 2009-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｐｐａｒモジュレーターとしての化合物および組成物
AR056786A1 (es) 2005-11-10 2007-10-24 Smithkline Beecham Corp Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
AU2006315334B2 (en) 2005-11-16 2011-05-19 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US7625896B2 (en) 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
JP5103403B2 (ja) 2005-12-05 2012-12-19 スミスクライン ビーチャム コーポレーション ２−ピリミジニルピラゾロピリジンＥｒｂＢキナーゼ阻害剤
US20070135368A1 (en) 2005-12-09 2007-06-14 Knapp Pamela E Cell-to-cell transmission of siRNA induced gene silencing in mammalian cells
US7799822B2 (en) 2005-12-21 2010-09-21 Vertex Pharmaceuticals Incorporated Phenyl sulfonamides as modulators of ion channels
KR20080091369A (ko) * 2006-01-18 2008-10-10 암젠 인크 단백질 키나제 ｂ （ｐｋｂ） 억제제로서 티아졸 화합물
AU2007208351C1 (en) 2006-01-23 2011-07-07 Amgen Inc. Aurora kinase modulators and method of use
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
TWI417096B (zh) 2006-01-25 2013-12-01 Synta Pharmaceuticals Corp 用於發炎及免疫相關用途之苯基及吡啶基化合物
US20070219239A1 (en) * 2006-02-10 2007-09-20 Mjalli Adnan M Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
PE20080176A1 (es) * 2006-03-31 2008-04-25 Glaxo Group Ltd Compuestos de arilpiperazina sulfonamida como agonista de los receptores de secretagogos de la hormona de crecimiento (ghs)
US7351434B2 (en) 2006-04-07 2008-04-01 Academia Sinica Therapeutic Gastrodia extracts
US20100179168A1 (en) * 2006-04-13 2010-07-15 Emma Louise Blaney Aryl and heteroaryl sulphonamides as growth hormone secretagogue receptor agonists
AU2006342509A1 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica, N.V. c-fms kinase inhibitors
ATE480525T1 (de) 2006-05-12 2010-09-15 Ab Science Neues verfahren zur synthese von 2- aminooxazolverbindungen
US8933130B2 (en) 2006-06-23 2015-01-13 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
PE20080401A1 (es) 2006-07-07 2008-06-23 Boehringer Ingelheim Int DERIVADOS DE HETEROARIL-FENIL SUSTITUIDOS COMO INHIBIDORES DE B-Raf-QUINASAS
US20080032990A1 (en) 2006-07-07 2008-02-07 Khalifah Raja G Inhibitors of advanced glycation end products
WO2008013928A2 (en) 2006-07-28 2008-01-31 Biogen Idec Ma Inc. Treatment of cancer with interferon gene delivery in combination with a tgf-beta inhibitor
US7994338B2 (en) 2006-08-16 2011-08-09 The J. David Gladstone Institutes Small molecule inhibitors of kynurenine-3-monooxygenase
EP2054056A4 (en) 2006-08-16 2010-08-25 J David Gladstone Inst A Testa SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE
GB0622202D0 (en) 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds
CA2913963A1 (en) 2006-12-08 2008-06-19 Millenium Pharmaceuticals, Inc. Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
AR064348A1 (es) 2006-12-15 2009-04-01 Bayer Schering Pharma Ag 3-h-pirazolopiridinas y sales de estas, composiciones farmaceuticas que las comprenden, metodos para prepararlas y sus usos
CA2677264C (en) 2007-02-02 2021-11-30 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9556491B2 (en) * 2007-02-26 2017-01-31 John Wayne Cancer Institute Utility of B-RAF DNA mutation in diagnosis and treatment of cancer
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
RU2009137190A (ru) 2007-03-08 2011-04-20 Плексксикон, Инк. (Us) Соединения, обладающие активностью в отношении ppar
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
WO2008129288A2 (en) 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
US20100234386A1 (en) * 2007-05-10 2010-09-16 Chaudhari Amita Quinoxaline derivatives as pi3 kinase inhibitors
AU2008251381B2 (en) 2007-05-11 2014-10-30 The Johns Hopkins University Biomarkers for melanoma
BRPI0811898A2 (pt) * 2007-06-01 2019-09-24 Glaxosmithkline Llc composto, composição farmacêutica, métodos para tratar um neoplasma suscetível e um câncer em um mamífero, processo para preparar um composto, e, uso de um composto.
CN107021895A (zh) 2007-06-12 2017-08-08 尔察祯有限公司 抗菌剂
WO2009003998A2 (en) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
WO2009010871A2 (en) 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as antagonists of adenosine a3 receptor
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
BRPI0814423B1 (pt) 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
EP2201562B1 (en) 2007-09-11 2018-04-25 University of Massachusetts Insulin-like growth factor binding protein 7 for treatment of cancer
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
AU2008323698A1 (en) 2007-11-09 2009-05-14 John Wayne Cancer Institute Utility of RET mutant in diagnosis and treatment of melanoma
GB0722680D0 (en) 2007-11-19 2007-12-27 Topotarget As Therapeutic compounds and their use
EP2231625A4 (en) 2007-12-13 2010-12-29 Glaxosmithkline Llc KINASE INHIBITORS BASED ON THIAZOLE AND OXAZOLE
AU2008351943B2 (en) 2007-12-18 2013-12-19 Sanofi-Aventis Azetidine derivatives, their preparation and their application in therapy
JPWO2009096198A1 (ja) 2008-02-01 2011-05-26 一般社団法人ファルマＩｐ 新規ビアリール誘導体
WO2009100214A2 (en) 2008-02-05 2009-08-13 The Johns Hopkins University Induction of thyroid iodide-handling gene expression in human cancers
JP2011511056A (ja) * 2008-02-05 2011-04-07 ファイザー・インク Ｃｎｓ障害および代謝障害治療のためのピリジニルアミド
US20090275546A1 (en) * 2008-04-10 2009-11-05 Istituto Superiore Di Sanita Diagnostic tests and personalized treatment regimes for cancer stem cells
US8198284B2 (en) * 2008-04-30 2012-06-12 National Health Research Institutes Treatment of neurodegenerative disorders with thiourea compounds
US8133884B2 (en) 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2303013A1 (en) 2008-07-07 2011-04-06 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same
BRPI0916356B1 (pt) 2008-07-24 2022-08-23 Nerviano Medical Sciences S.R.L 3,4-diaril pirazois como inibidores da proteína quinase
MX2011001349A (es) 2008-08-04 2011-08-17 Chidi Inc Ciertos inhibidores de quinurenin-3-monooxigenasa, composiciones farmaceuticas y metodos para su uso.
WO2010018458A2 (en) 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
US20110319415A1 (en) 2008-08-18 2011-12-29 Universit+e,uml a+ee t zu K+e,uml o+ee ln Susceptibility to HSP90-Inhibitors
GB0815947D0 (en) 2008-09-02 2008-10-08 Univ Dundee Compounds
US8499305B2 (en) 2010-10-15 2013-07-30 Via Technologies, Inc. Systems and methods for performing multi-program general purpose shader kickoff

Also Published As

Publication number Publication date
HRP20160447T1 (hr) 2016-05-20
HUE028820T2 (en) 2017-01-30
US20090298815A1 (en) 2009-12-03
EP2282636A2 (en) 2011-02-16
SG190624A1 (en) 2013-06-28
IL209018A0 (en) 2011-01-31
AU2009244491B2 (en) 2014-08-07
ZA201007960B (en) 2012-04-25
MA32369B1 (fr) 2011-06-01
CA2723396C (en) 2013-09-10
DK2282636T3 (en) 2016-05-02
SI2282636T1 (sl) 2016-06-30
WO2009137391A2 (en) 2009-11-12
EP2282636A4 (en) 2012-06-13
US20140080851A1 (en) 2014-03-20
BRPI0912541B1 (pt) 2021-05-11
BRPI0912541A2 (pt) 2020-08-04
US8415345B2 (en) 2013-04-09
CL2009001065A1 (es) 2010-12-31
JP2011519940A (ja) 2011-07-14
ES2576684T3 (es) 2016-07-08
NZ588970A (en) 2012-06-29
CA2723396A1 (en) 2009-11-12
US9233956B2 (en) 2016-01-12
TWI432430B (zh) 2014-04-01
CY1117615T1 (el) 2017-04-26
IL209018A (en) 2015-08-31
US8642759B2 (en) 2014-02-04
MY155317A (en) 2015-09-30
EP2282636B1 (en) 2016-03-23
MX2010012074A (es) 2011-03-21
WO2009137391A3 (en) 2009-12-30
US20160068523A1 (en) 2016-03-10
EP3106462A1 (en) 2016-12-21
US7994185B2 (en) 2011-08-09
CN102083312A (zh) 2011-06-01
US20130144055A1 (en) 2013-06-06
AU2009244491A1 (en) 2009-11-12
PE20091952A1 (es) 2010-01-21
JO3408B1 (ar) 2019-10-20
US20170073341A1 (en) 2017-03-16
EA201001680A1 (ru) 2011-06-30
UY31806A (es) 2009-12-14
HK1147907A1 (zh) 2011-08-26
UA103319C2 (en) 2013-10-10
RS54725B1 (sr) 2016-10-31
BRPI0912541B8 (pt) 2021-05-25
CO6321189A2 (es) 2011-09-20
KR20110013456A (ko) 2011-02-09
DOP2010000326A (es) 2010-12-15
JP5426664B2 (ja) 2014-02-26
TW200951130A (en) 2009-12-16
US20110172215A1 (en) 2011-07-14
KR101628746B1 (ko) 2016-06-13
CN102083312B (zh) 2014-08-27
PL2282636T3 (pl) 2016-08-31
EA019349B1 (ru) 2014-03-31

Similar Documents

Publication Publication Date Title
AR071617A1 (es) Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos.
PE20210396A1 (es) Moduladores de la via de estres integrada
AR082201A1 (es) Bencenosulfonamidas utiles como inhibidores del canal de sodio
PE20210004A1 (es) Inhibidores de mcl-1
AR082153A1 (es) N-sulfonilbenzamidas utiles como inhibidor del canal de sodio
PE20070189A1 (es) COMPUESTO DE AMINO-5-HETEROARILO (5 MIEMBROS) IMIDAZOLONA Y SU USO PARA MODULACION DE LA ß-SECRETASA
PE20221253A1 (es) Inhibidores de pequenas moleculas de mutante g12c de kras
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
ECSP067013A (es) 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4
PE20140863A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
AR071644A1 (es) Plaguicidas mesoionicos
AR081932A1 (es) Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
CO5590957A2 (es) Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas
PE20140171A1 (es) Pirazoles fungicidas y sus mezclas
AR059176A1 (es) Compuesto de indol, composicion farmaceutica que lo comprende, metodo para prepararlo y su uso para preparar dicha composicion y para la manufactura de un medicamento para el tratamiento o prevencion de leiomiomas y endometriosis.
AR076460A1 (es) Antagonistas del receptor cxcr3
PE20090549A1 (es) Derivados de imidazolidinona con actividad sobre lxr-alfa y lxr-beta
ECSP11010901A (es) Compuestos de amida útiles en terapia

Legal Events

Date Code Title Description
FG Grant, registration